Factors associated with major infection and GVHD
| . | Major infection . | Acute GVHD grades I-IV . | Acute GVHD grades II-IV . | |||
|---|---|---|---|---|---|---|
| CIF plus or minus SE . | P . | CIF plus or minus SE . | P . | CIF plus or minus SE . | P . | |
| Disease risk | .035 | .981 | .382 | |||
| Standard | 30.4 ± 6.9 | 50 ± 7.5 | 26.1 ± 6.6 | |||
| High | 50.3 ± 5.2 | 50.3 ± 5.1 | 33.6 ± 4.9 | |||
| Female donor, male recipient | .87 | .456 | .065 | |||
| No | 44.4 ± 4.8 | 52.2 ± 4.8 | 35. 1 ± 4.6 | |||
| Yes | 41.9 ± 9.1 | 42.9 ± 9.3 | 16.4 ± 6.8 | |||
| Stem cell source | .49 | .012 | .005 | |||
| Bone marrow | 62.5 ± 19.2 | 87.5 ± 15.4 | 75.0 ± 17.9 | |||
| Peripheral blood | 42.7 ± 4.3 | 48.0 ± 4.4 | 28. 5 ± 3.9 | |||
| Conditioning | .232 | .230 | .920 | |||
| Reduced intensity | 37.3 ± 6.4 | 46.4 ± 6.6 | 32.7 ± 6.2 | |||
| Myeloablative | 48.5 ± 5.6 | 53 ± 5.5 | 30.1 ± 5 | |||
| mTBI | .001 | .999 | .727 | |||
| No mTBI | 33.7 ± 5.0 | 51.5 ± 5.3 | 30.7 ± 4.9 | |||
| mTBI | 62.7 ± 7.0 | 48 ± 7.2 | 32 ± 6.7 | |||
| Decontamination | .001 | .040 | .501 | |||
| None | 61.4 ± 6.0 | 42 ± 6 | 27.5 ± 5.4 | |||
| Norfloxacin | 34.1 ± 7.3 | 52.3 ± 7.7 | 32.1 ± 7.2 | |||
| Ciprofloxacin & metronidazole | 17.2 ± 7.1 | 65.5 ± 9.1 | 37.9 ± 9.2 | |||
| Decontamination | .003 | .007 | .050 | |||
| None | 61.4 ± 6.0 | 38.0 ± 7.0 | 22 ± 5.9 | |||
| Any | 34.8 ± 5.0 | 57.0 ± 5.2 | 36.1 ± 5.1 | |||
| Immunosuppression | .039 | .241 | .21 | |||
| No steroid | 38.6 ± 4.9 | 52.9 ± 5 | 33.9 ± 4.8 | |||
| Steroid containing | 57.1 ± 8.2 | 43.6 ± 0.08 | 23.1 ± 6.8 | |||
| Recipient mutation | .17 | .102 | .51 | |||
| No mutation | 40.0 ± 5.1 | 47.7 ± 5.2 | 30.3 ± 4.8 | |||
| Mutation | 54.5 ± 7.6 | 59 ± 7.6 | 34.1 ± 7.2 | |||
| Recipient MBL2 insufficiency | .665 | .046 | .043 | |||
| Sufficient | 45.8 ± 4.8 | 47.6 ± 5.8 | 27.8 ± 4.3 | |||
| Insufficient | 40.0 ± 10.1 | 68 ± 9.7 | 48 ± 10.3 | |||
| Donor mutation | .041 | .460 | .872 | |||
| No mutation | 38.3 ± 5.4 | 48.1 ± 5.5 | 32.4 ± 5.2 | |||
| Mutation | 54.7 ± 6.9 | 54.7 ± 6.9 | 30.2 ± 6.4 | |||
| Donor MBL2-insufficient genotypes | .63 | .525 | .751 | |||
| Sufficient | 43.1 ± 5.2 | 48.8 ± 5.3 | 31 ± 4.9 | |||
| Insufficient | 47.8 ± 7.5 | 54.3 ± 7.5 | 32.6 ± 7 | |||
| . | Major infection . | Acute GVHD grades I-IV . | Acute GVHD grades II-IV . | |||
|---|---|---|---|---|---|---|
| CIF plus or minus SE . | P . | CIF plus or minus SE . | P . | CIF plus or minus SE . | P . | |
| Disease risk | .035 | .981 | .382 | |||
| Standard | 30.4 ± 6.9 | 50 ± 7.5 | 26.1 ± 6.6 | |||
| High | 50.3 ± 5.2 | 50.3 ± 5.1 | 33.6 ± 4.9 | |||
| Female donor, male recipient | .87 | .456 | .065 | |||
| No | 44.4 ± 4.8 | 52.2 ± 4.8 | 35. 1 ± 4.6 | |||
| Yes | 41.9 ± 9.1 | 42.9 ± 9.3 | 16.4 ± 6.8 | |||
| Stem cell source | .49 | .012 | .005 | |||
| Bone marrow | 62.5 ± 19.2 | 87.5 ± 15.4 | 75.0 ± 17.9 | |||
| Peripheral blood | 42.7 ± 4.3 | 48.0 ± 4.4 | 28. 5 ± 3.9 | |||
| Conditioning | .232 | .230 | .920 | |||
| Reduced intensity | 37.3 ± 6.4 | 46.4 ± 6.6 | 32.7 ± 6.2 | |||
| Myeloablative | 48.5 ± 5.6 | 53 ± 5.5 | 30.1 ± 5 | |||
| mTBI | .001 | .999 | .727 | |||
| No mTBI | 33.7 ± 5.0 | 51.5 ± 5.3 | 30.7 ± 4.9 | |||
| mTBI | 62.7 ± 7.0 | 48 ± 7.2 | 32 ± 6.7 | |||
| Decontamination | .001 | .040 | .501 | |||
| None | 61.4 ± 6.0 | 42 ± 6 | 27.5 ± 5.4 | |||
| Norfloxacin | 34.1 ± 7.3 | 52.3 ± 7.7 | 32.1 ± 7.2 | |||
| Ciprofloxacin & metronidazole | 17.2 ± 7.1 | 65.5 ± 9.1 | 37.9 ± 9.2 | |||
| Decontamination | .003 | .007 | .050 | |||
| None | 61.4 ± 6.0 | 38.0 ± 7.0 | 22 ± 5.9 | |||
| Any | 34.8 ± 5.0 | 57.0 ± 5.2 | 36.1 ± 5.1 | |||
| Immunosuppression | .039 | .241 | .21 | |||
| No steroid | 38.6 ± 4.9 | 52.9 ± 5 | 33.9 ± 4.8 | |||
| Steroid containing | 57.1 ± 8.2 | 43.6 ± 0.08 | 23.1 ± 6.8 | |||
| Recipient mutation | .17 | .102 | .51 | |||
| No mutation | 40.0 ± 5.1 | 47.7 ± 5.2 | 30.3 ± 4.8 | |||
| Mutation | 54.5 ± 7.6 | 59 ± 7.6 | 34.1 ± 7.2 | |||
| Recipient MBL2 insufficiency | .665 | .046 | .043 | |||
| Sufficient | 45.8 ± 4.8 | 47.6 ± 5.8 | 27.8 ± 4.3 | |||
| Insufficient | 40.0 ± 10.1 | 68 ± 9.7 | 48 ± 10.3 | |||
| Donor mutation | .041 | .460 | .872 | |||
| No mutation | 38.3 ± 5.4 | 48.1 ± 5.5 | 32.4 ± 5.2 | |||
| Mutation | 54.7 ± 6.9 | 54.7 ± 6.9 | 30.2 ± 6.4 | |||
| Donor MBL2-insufficient genotypes | .63 | .525 | .751 | |||
| Sufficient | 43.1 ± 5.2 | 48.8 ± 5.3 | 31 ± 4.9 | |||
| Insufficient | 47.8 ± 7.5 | 54.3 ± 7.5 | 32.6 ± 7 | |||
Univariate associations with infection, incorporating consideration of noninfective death as a competing risk, are shown.
CIF indicates cumulative incidence fraction; SE, standard error; and mTBI, myeloablative TBI.